Prognosis stratification tools in early-stage endometrial cancer: could we improve their accuracy?
Author
Ramon-Patino, Jorge Luis; Ruz-Caracuel, Ignacio; Heredia-Soto, Victoria; García de la Calle, Luis Eduardo; Zagidullin, Bulat; Wang, Yinyin; Berjón, Alberto; López-Janeiro, Álvaro; Miguel, María; Escudero, Javier; Gallego, Alejandro; Castelo Fernández, Beatriz; Yébenes, Laura; Hernández Gutiérrez, María Alicia; Feliú Batlle, Jaime; Pelaez-García, Alberto; Tang, Jing; Hardisson Hernáez, David Alonso; Mendiola, Marta; Redondo Sánchez, AndrésEntity
UAM. Departamento de Anatomía Patológica; UAM. Departamento de Medicina; UAM. Departamento de Obstetricia y GinecologíaPublisher
MDPIDate
2022-02-12Citation
10.3390/cancers14040912
Cancers 14.4 (2022): 912
ISSN
2072-6694 (online)DOI
10.3390/cancers14040912Funded by
This research was funded by the Instituto de Salud Carlos III (ISCIII), cofinanced by the European Development Regional Fund ‘A way to achieve Europe’ (FEDER, PI17/01723 to D.H.), and by Academy of Finland grant (No. 317680 to J.T.). B.Z. is supported by the faculty funded PhD position in the Integrative Life Science Doctoral Programme, University of HelsinkiProject
Gobierno de España. PI17/01723Editor's Version
https://doi.org/10.3390/cancers14040912Subjects
Biomarkers; CTNNB1; Endometrial cancer; Prognosis; Risk assessment; MedicinaRights
© 2022 by the authorsAbstract
There are three prognostic stratification tools used for endometrial cancer: ESMO-ESGO-ESTRO 2016, ProMisE, and ESGO-ESTRO-ESP 2020. However, these methods are not sufficiently accurate to address prognosis. The aim of this study was to investigate whether the integration of molecular classification and other biomarkers could be used to improve the prognosis stratification in early-stage endometrial cancer. Relapse-free and overall survival of each classifier were analyzed, and the c-index was employed to assess accuracy. Other biomarkers were explored to improve the precision of risk classifiers. We analyzed 293 patients. A comparison between the three classifiers showed an improved accuracy in ESGO-ESTRO-ESP 2020 when RFS was evaluated (c-index = 0.78), although we did not find broad differences between intermediate prognostic groups. Prognosis of these patients was better stratified with the incorporation of CTNNB1 status to the 2020 classifier (c-index 0.81), with statistically significant and clinically relevant differences in 5-year RFS: 93.9% for low risk, 79.1% for intermediate merged group/CTNNB1 wild type, and 42.7% for high risk (includ-ing patients with CTNNB1 mutation). The incorporation of molecular classification in risk stratification resulted in better discriminatory capability, which could be improved even further with the addition of CTNNB1 mutational evaluation
Files in this item
Google Scholar:Ramon-Patino, Jorge Luis
-
Ruz-Caracuel, Ignacio
-
Heredia-Soto, Victoria
-
García de la Calle, Luis Eduardo
-
Zagidullin, Bulat
-
Wang, Yinyin
-
Berjón, Alberto
-
López-Janeiro, Álvaro
-
Miguel, María
-
Escudero, Javier
-
Gallego, Alejandro
-
Castelo Fernández, Beatriz
-
Yébenes, Laura
-
Hernández Gutiérrez, María Alicia
-
Feliú Batlle, Jaime
-
Pelaez-García, Alberto
-
Tang, Jing
-
Hardisson Hernáez, David Alonso
-
Mendiola, Marta
-
Redondo Sánchez, Andrés
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling
López-Janeiro, Álvaro; Ruz-Caracuel, Ignacio; Ramón-Patino, Jorge L.; Ríos, Vivian De Los; Esparza, María Villalba; Berjón, Alberto; Yébenes, Laura; Hernández, Alicia; Masetto, Ivan; Kadioglu, Ece; Goubert, Virginie; Heredia-Soto, Victoria; Barderas, Rodrigo; Casal, José Ignacio; de Andrea, Carlos E.; Redondo Sánchez, Andrés; Mendiola, Marta; Peláez-García, Alberto; Hardisson Hernáez, David Alonso
2021-02-14